Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2023-02-02 Major Shareholding Noti…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
持股5%以上股东减持股份计划公告（再次披露）
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder holding more than 5% of the company's shares planning to reduce their holdings. It includes details about the shareholder, the number and percentage of shares to be reduced, the method and timing of the reduction, compliance statements, and risk disclosures. There is no financial data, earnings information, or management discussion. The document is a regulatory announcement about a major shareholding change, specifically a reduction in shares held by a significant shareholder. This fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on this topic, confirming it is not a full report or other type of filing.
2023-02-02 Chinese
实际控制人的一致行动人减持股份进展公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the progress of shareholding reduction by a related party (actual controller's concerted action person) of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the number of shares held before and after reduction, the method of reduction, timing, and risk warnings. There is no financial data, earnings, or management discussion. The content focuses on shareholding changes by a significant shareholder, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short and it is not an announcement of a report publication or certification. Therefore, the appropriate classification is MRQ.
2023-02-02 Chinese
实际控制人的一致行动人减持股份进展公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding the progress of share reduction by a shareholder who is an acting-in-concert party of the actual controller. It details the shareholder's holdings, the status of the share reduction plan, and risk disclosures related to the share reduction. There is no financial report, earnings data, or management discussion. The document is a notification about a transaction in the company's own shares by a significant shareholder or related party. This fits the category of 'Transaction in Own Shares' (POS). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS. Therefore, the classification is POS with high confidence.
2023-01-29 Chinese
关于收到政府上市奖励的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (464 characters) about the company receiving a government listing reward. It includes a statement about the accounting treatment of the government subsidy and a caution to investors. There is no financial data, no detailed report, and no mention of an attached or forthcoming report. It is an announcement of a government subsidy receipt, not a financial report or detailed filing. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2023-01-29 Chinese
关于公司产品新纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the inclusion of a new product into the National Medical Insurance Directory. It contains no financial statements, no detailed financial data, no management discussion of financial results, nor any regulatory filings or voting results. It is a regulatory announcement about product listing and its potential impact on the company. The document is short (680 characters) and is an official company disclosure. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-01-18 Chinese
关于公司药品生产许可证变更的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the change of its drug production license issued by a regulatory authority (Sichuan Provincial Drug Administration). It details the updated license information, the scope of production, and the impact on the company. The document is short (973 characters) and serves as a formal notification to investors and the public about a regulatory compliance update rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement but a regulatory announcement about licensing. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-01-18 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.